{{Rsnum
|rsid=7046653
|Gene=MOBKL2B
|Chromosome=9
|position=27490969
|Orientation=plus
|GMAF=0.3701
|Gene_s=MOB3B
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 9.7 | 38.1 | 52.2
| HCB | 14.6 | 41.6 | 43.8
| JPT | 4.4 | 34.5 | 61.1
| YRI | 37.4 | 48.3 | 14.3
| ASW | 15.8 | 59.6 | 24.6
| CHB | 14.6 | 41.6 | 43.8
| CHD | 17.6 | 44.4 | 38.0
| GIH | 7.9 | 39.6 | 52.5
| LWK | 32.7 | 50.0 | 17.3
| MEX | 13.8 | 51.7 | 34.5
| MKK | 32.9 | 51.0 | 16.1
| TSI | 7.8 | 44.1 | 48.0
| HapMapRevision=28
}}

{{GWAS Summary
|SNP=rs7046653
|PubMedID=18615156
|Condition=Treatment response to TNF antagonists
|Gene=IFNK
|Risk Allele=A
|pValue=5.00E-007
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs7046653
|Name_s=
|Gene_s=MOBKL2B
|Feature=
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.0000005; OR: 4.9 (1.8, 14.0)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928826
}}

{{PharmGKB
|RSID=rs7046653
|Name_s=
|Gene_s=MOBKL2B
|Feature=
|Evidence=PubMed ID:18615156; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in Rheumatoid Arthritis (Initial Sample Size: 89 cases; Replication Sample Size: NR; Risk Allele: rs7046653-A). This variant is associated with Treatment response to TNF antagonists.
|Drugs=
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356480
}}

{{PMID|20423481|OA=1
}} Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7046653
|overall_frequency_n=75
|overall_frequency_d=128
|overall_frequency=0.585938
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=65
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}